Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort studyFrancesco Passamonti, Celestino Ferrandina, Monia Marchetti et al.|The Lancet Haematology|2020Cited by 553
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristicsPaul G. Richardson, Meletios Α. Dimopoulos, Fredrik Schjesvold et al.|European Journal Of Haematology|2021Cited by 11
Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and RussiaGordon Cook, María‐Victoria Mateos, Alessandro Corso et al.|Oncology and Therapy|2021Cited by 9
The VAD-DCEP sequence is an effective pre-transplant therapy in untreated multiple myeloma.Alessandro Corso, Mario Lazzarino, Luciana Barbarano et al.|PubMed|2004Cited by 5
Bendamustine, Low-Dose Dexamethasone, and Lenalidomide (BdL) For The Treatment Of Patients With Relapsed Multiple Myeloma Confirms Very Promising Results In a Phase I/II StudySamantha Pozzi, Stefano Sacchi, Stefania Badiali et al.|Blood|2013Cited by 4